查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1600974

吸入和鼻喷雾的学名药市场：按适应症、年龄层、药物类别、路线和分销管道 - 2025-2030 年全球预测

Inhalation & Nasal Sprays Generic Drugs Market by Indication (Allergic Rhinitis, Asthma, COPD), Age Group (Adults, Children 2 to 5, Children 6 to 12), Class, Route, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年吸入器和鼻喷雾的学名药市值为80.9亿美元，预计2024年将达到87.8亿美元，复合年增长率为8.61%，到2030年将达到14.4亿美元，预计将达到3000万美元。

学名药药吸入器和鼻喷雾市场范围涵盖主要用于气喘、慢性阻塞性肺病和过敏性鼻炎等呼吸系统疾病的频谱药物。这些学名药为品牌药提供了具有成本效益的替代品，并扩大了获得基本治疗方法的机会。对学名药的需求源于世界各地呼吸系统疾病和过敏的日益流行，仿製药主要用于医院、诊所和居家医疗机构。最终用途范围跨越年龄组，针对儿童和成人。影响成长的因素包括慢性呼吸道疾病盛行率上升、政府推广学名药使用的努力以及控制医疗费用的措施。此外，几种重磅吸入药物的专利已经到期，为学名药​​製造商创造了利润丰厚的商机。扩大我们的地理覆盖范围存在潜在的机会，特别是在对具有成本效益的医疗保健解决方案的需求不断增加的新兴市场。简化您的监管核准流程并加强您的分销网络，以进一步增强您的市场影响力。然而，市场成长面临严格的监管障碍、领先公司之间的激烈竞争以及学名药与品牌药相比生物等效性的潜在问题等挑战。有限的製造能力以及需要高额研发投资以实现治疗等效性和设备创新也是主要障碍。在创新方面，先进药物输送系统的开发存在成长机会，例如可以提高依从性并提供即时使用资料的数位吸入器。潜在的研究领域包括研究个人化医疗、针对特定患者群体优化配方以及专注于吸入器的环保推进剂。市场是充满活力和竞争的，不断进步增加了策略创新和适应的需求，以有效占领市场占有率。

主要市场统计
基准年[2023] 80.9亿美元
预测年份 [2024] 87.8亿美元
预测年份 [2030] 144.3亿美元
复合年增长率（%） 8.61%

市场动态：吸入器和鼻喷雾快速发展的学名药市场的关键市场洞察

供需的动态交互作用正在改变吸入器和鼻喷雾的学名药市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 仿製药非专利药的成本较低
    • 呼吸道疾病盛行率增加
    • 儿科雾化器的显着普及
  • 市场限制因素
    • 对学名药的严格监管
  • 市场机会
    • 重磅药物专利到期和 FDA核准增加
    • 药厂加大研发投入
  • 市场挑战
    • 由于该细分市场存在多个参与者而造成价格压力

波特五力：开拓吸入器和鼻喷雾学名药市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对吸入器和鼻喷雾学名药市场的影响

外部宏观环境因素在塑造学名药药吸入和鼻喷雾市场的业绩动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解吸入器和鼻喷雾学名药市场的竞争状况

对学名药吸入和鼻喷雾市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位基质吸入和鼻喷雾学名药市场供应商绩效评估

FPNV定位矩阵是评估学名药药吸入和鼻喷雾市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。四个象限清楚且准确地划分了供应商，帮助使用者辨识最能满足其策略目标的合作伙伴和解决方案。

本报告提供了涵盖关键重点领域的全面市场分析：

1. 市场渗透率：对当前市场环境的详细回顾，包括行业主要企业的大量资料。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 学名药成本低
      • 呼吸道疾病盛行率增加
      • 儿科雾化器重要介绍
    • 抑制因素
      • 对学名药的严格监管
    • 机会
      • 重磅药物专利到期和 FDA核准数量增加
      • 药厂加大研发投入
    • 任务
      • 多个参与者的存在增加了价格压力
  • 市场区隔分析
    • 适应症：需要使用治疗过敏性鼻炎的学名药快速、即时缓解症状
    • 年龄层：加强2~5岁儿童产品研发
    • 分销管道：网路药局变得越来越受欢迎，因为它们提供有竞争力的价格和便利性。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境
  • 客户客製化
    • 处方和给药装置的变更

第六章 吸入器和鼻喷雾的适应症学名药市场

  • 过敏性鼻炎
  • 气喘
  • 慢性阻塞性肺病

第七章 吸入器和鼻喷雾的学名药市场：按年龄组

  • 成人
  • 2岁至5岁儿童
  • 6至12岁儿童

第八章吸入器和鼻喷雾的学名药市场：按类别

  • 过敏阻断剂
  • 抗胆碱能药
  • 抗组织胺药
  • 减充血剂
  • 肥大细胞抑制剂
  • 鼻类固醇

第九章 吸入器和鼻喷雾的学名药市场：按途径

  • 吸入
  • 鼻喷剂
  • 热带乳液

第十章吸入器和鼻喷雾的学名药市场：按分销渠道

  • 医院医疗用品店
  • 网路药房
  • 药局零售业

第十一章 美洲吸入器和鼻喷雾的学名药市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章 亚太地区吸入器和鼻喷雾学名药市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲吸入器和鼻喷雾学名药市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Usea Pharma非专利Budesonide获得美国FDA核准
    • Amphastar Pharmaceuticals 的盐酸纳洛酮鼻滴鼻剂4 毫克获得 FDA核准
    • Amneal 宣布其盐酸纳洛酮滴鼻剂（USP，4mg）的简化新药申请已被美国FDA 受理

公司名单

  • Chiesi Farmaceutici SpA
  • Altaire Pharmaceuticals Inc.
  • Apotex Inc.
  • Amphastar Pharmaceuticals, Inc.
  • Hikma Pharmaceuticals PLC
  • Sun Pharmaceutical Industries Ltd.
  • Cipla Limited
  • AstraZeneca PLC
  • Sandoz International GmbH
  • Viatris Inc.
  • AbbVie Inc.
  • Nephron Pharmaceuticals Corporation
  • Zhejiang Xianju Pharmaceutical Co., Ltd.
  • Preferred Pharmaceuticals, Inc.
  • Acerus Pharmaceuticals Corporation
  • Mylan NV
  • Beximco Pharmaceuticals Ltd.
  • Akorn, Inc.
  • Perrigo Company PLC
  • GlaxoSmithKline PLC
  • Nippon Shinyaku Co., Ltd.
  • Sanofi SA
  • Padagis US LLC
  • AptarGroup, Inc.
  • Recipharm AB
  • Teva Pharmaceutical Industries Ltd.
  • Catalent, Inc.
Product Code: MRR-032A67D9141A

The Inhalation & Nasal Sprays Generic Drugs Market was valued at USD 8.09 billion in 2023, expected to reach USD 8.78 billion in 2024, and is projected to grow at a CAGR of 8.61%, to USD 14.43 billion by 2030.

The scope of the inhalation and nasal sprays generic drugs market encompasses a wide spectrum of medications used primarily for respiratory conditions such as asthma, COPD, and allergic rhinitis. These generic drugs offer cost-effective alternatives to branded medications, expanding access to essential therapies. Necessity for these drugs arises from the increasing prevalence of respiratory diseases and allergies worldwide, fueling their application primarily in hospitals, clinics, and homecare settings. End-use scope spans across age groups, catering to both pediatric and adult populations. Influencing growth factors include the rising incidence of chronic respiratory ailments, government initiatives to promote generic drug usage, and healthcare cost containment measures. Additionally, the expiration of patents for several blockbuster inhalation drugs opens lucrative opportunities for generics manufacturers. Potential opportunities lie in expanding geographical reach, particularly in emerging markets where demand for cost-effective healthcare solutions is mounting. Streamlining the regulatory approval process and enhancing distribution networks can further solidify market presence. Yet, market growth faces challenges such as stringent regulatory hurdles, high competition among leading players, and potential issues related to the bioequivalence of generics compared to brand-name counterparts. Limitations in manufacturing capabilities and the necessity for high investment in R&D to achieve therapeutic equivalence and device innovation are also significant barriers. On the innovation front, opportunities for growth lie in the development of advanced drug-delivery systems, such as digital inhalers that improve adherence and provide real-time usage data. Research into personalized medicine, optimizing formulations to target specific patient demographics, and focusing on eco-friendly propellants in inhalers are other potential areas of exploration. The market is dynamic and competitive, with continuous advancements fostering a need for strategic innovation and adaptation to capture market share effectively.

KEY MARKET STATISTICS
Base Year [2023] USD 8.09 billion
Estimated Year [2024] USD 8.78 billion
Forecast Year [2030] USD 14.43 billion
CAGR (%) 8.61%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Inhalation & Nasal Sprays Generic Drugs Market

The Inhalation & Nasal Sprays Generic Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Low Cost Involved with Generic Prescription Drugs
    • Increasing Prevalence of Respiratory Diseases
    • Significant Adoption of Nebulizers for Children
  • Market Restraints
    • Stringent Regulations For Generic Drugs
  • Market Opportunities
    • Patent Expiry of Blockbuster Drugs and Increasing FDA Approvals
    • Growing Investments from Pharmaceutical Companies for R&D
  • Market Challenges
    • Pricing Pressure due to Presence of Multiple Players in the Segment

Porter's Five Forces: A Strategic Tool for Navigating the Inhalation & Nasal Sprays Generic Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Inhalation & Nasal Sprays Generic Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Inhalation & Nasal Sprays Generic Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Inhalation & Nasal Sprays Generic Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Inhalation & Nasal Sprays Generic Drugs Market

A detailed market share analysis in the Inhalation & Nasal Sprays Generic Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Inhalation & Nasal Sprays Generic Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Inhalation & Nasal Sprays Generic Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Inhalation & Nasal Sprays Generic Drugs Market, highlighting leading vendors and their innovative profiles. These include Chiesi Farmaceutici S.p.A., Altaire Pharmaceuticals Inc., Apotex Inc., Amphastar Pharmaceuticals, Inc., Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Cipla Limited, AstraZeneca PLC, Sandoz International GmbH, Viatris Inc., AbbVie Inc., Nephron Pharmaceuticals Corporation, Zhejiang Xianju Pharmaceutical Co., Ltd., Preferred Pharmaceuticals, Inc., Acerus Pharmaceuticals Corporation, Mylan N.V., Beximco Pharmaceuticals Ltd., Akorn, Inc., Perrigo Company PLC, GlaxoSmithKline PLC, Nippon Shinyaku Co., Ltd., Sanofi S.A., Padagis US LLC, AptarGroup, Inc., Recipharm AB, Teva Pharmaceutical Industries Ltd., and Catalent, Inc..

Market Segmentation & Coverage

This research report categorizes the Inhalation & Nasal Sprays Generic Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Indication, market is studied across Allergic Rhinitis, Asthma, and COPD.
  • Based on Age Group, market is studied across Adults, Children 2 to 5, and Children 6 to 12.
  • Based on Class, market is studied across Allergy Blocker, Anticholinergic, Antihistamine, Decongestant, Mast Cell Inhibitor, and Nasal Steroid.
  • Based on Route, market is studied across Inhalation, Nasal Spray, and Tropical Lotion.
  • Based on Distribution Channel, market is studied across Hospital Medical Store, Online Pharmacy, and Pharmacy Retail.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Low Cost Involved with Generic Prescription Drugs
      • 5.1.1.2. Increasing Prevalence of Respiratory Diseases
      • 5.1.1.3. Significant Adoption of Nebulizers for Children
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent Regulations For Generic Drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Patent Expiry of Blockbuster Drugs and Increasing FDA Approvals
      • 5.1.3.2. Growing Investments from Pharmaceutical Companies for R&D
    • 5.1.4. Challenges
      • 5.1.4.1. Pricing Pressure due to Presence of Multiple Players in the Segment
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Indication: Need for quick and immediate symptom relief generic medications for allergic rhinitis
    • 5.2.2. Age Group: Increasing product development for children aged 2 to 5
    • 5.2.3. Distribution Channel: Growing popularity of online pharmacies offering competitive pricing and convenience
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization
    • 5.5.1. Changing Formulation & Delivery Device

6. Inhalation & Nasal Sprays Generic Drugs Market, by Indication

  • 6.1. Introduction
  • 6.2. Allergic Rhinitis
  • 6.3. Asthma
  • 6.4. COPD

7. Inhalation & Nasal Sprays Generic Drugs Market, by Age Group

  • 7.1. Introduction
  • 7.2. Adults
  • 7.3. Children 2 to 5
  • 7.4. Children 6 to 12

8. Inhalation & Nasal Sprays Generic Drugs Market, by Class

  • 8.1. Introduction
  • 8.2. Allergy Blocker
  • 8.3. Anticholinergic
  • 8.4. Antihistamine
  • 8.5. Decongestant
  • 8.6. Mast Cell Inhibitor
  • 8.7. Nasal Steroid

9. Inhalation & Nasal Sprays Generic Drugs Market, by Route

  • 9.1. Introduction
  • 9.2. Inhalation
  • 9.3. Nasal Spray
  • 9.4. Tropical Lotion

10. Inhalation & Nasal Sprays Generic Drugs Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Medical Store
  • 10.3. Online Pharmacy
  • 10.4. Pharmacy Retail

11. Americas Inhalation & Nasal Sprays Generic Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Inhalation & Nasal Sprays Generic Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Inhalation & Nasal Sprays Generic Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Eugia Pharma Gets USFDA Nod for Budesonide Generic
    • 14.3.2. Amphastar Pharmaceuticals Receives FDA Approval for Naloxone Hydrochloride Nasal Spray 4mg
    • 14.3.3. Amneal Announces U.S. FDA Filing Acceptance of Abbreviated New Drug Application for Naloxone Hydrochloride Nasal Spray, USP, 4mg

Companies Mentioned

  • 1. Chiesi Farmaceutici S.p.A.
  • 2. Altaire Pharmaceuticals Inc.
  • 3. Apotex Inc.
  • 4. Amphastar Pharmaceuticals, Inc.
  • 5. Hikma Pharmaceuticals PLC
  • 6. Sun Pharmaceutical Industries Ltd.
  • 7. Cipla Limited
  • 8. AstraZeneca PLC
  • 9. Sandoz International GmbH
  • 10. Viatris Inc.
  • 11. AbbVie Inc.
  • 12. Nephron Pharmaceuticals Corporation
  • 13. Zhejiang Xianju Pharmaceutical Co., Ltd.
  • 14. Preferred Pharmaceuticals, Inc.
  • 15. Acerus Pharmaceuticals Corporation
  • 16. Mylan N.V.
  • 17. Beximco Pharmaceuticals Ltd.
  • 18. Akorn, Inc.
  • 19. Perrigo Company PLC
  • 20. GlaxoSmithKline PLC
  • 21. Nippon Shinyaku Co., Ltd.
  • 22. Sanofi S.A.
  • 23. Padagis US LLC
  • 24. AptarGroup, Inc.
  • 25. Recipharm AB
  • 26. Teva Pharmaceutical Industries Ltd.
  • 27. Catalent, Inc.

LIST OF FIGURES

  • FIGURE 1. INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ASTHMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COPD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CHILDREN 2 TO 5, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CHILDREN 6 TO 12, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ALLERGY BLOCKER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ANTICHOLINERGIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ANTIHISTAMINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DECONGESTANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY MAST CELL INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY NASAL STEROID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY NASAL SPRAY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY TROPICAL LOTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY HOSPITAL MEDICAL STORE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY PHARMACY RETAIL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 239. INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 240. INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023